1.Ahn JS，Park S，Im SA，et al. High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Korean J Intern Med，2005，20：224-231.

2.Hopman RK，and Dipersio JF. Advances in StemCell mobilization. Blood Rev，2014，28：31-40.

3.Giralt S，Costa L，Schriber J，et al. Optimizing autologous mobiliazation strategies to improved patient outcomes：Consensus guideline and Recommendations. Biol Blood Marrow Transplant，2014，20：295-308.

4.Costa LJ，Miller AN，Alexander ET，et al. Growth factor and patient adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant，2011，46：523-528.

5.Fu P，Bagai RK，Meyerson H，et al. Premobilization therapy blood CD34 ⁺ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant，2006，38：189-196.

6.Olivieri A，Marchetti M，Lemoli RM，et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma：An analytic hierarchy process by adhoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplantation，2012，47：342-351.